Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:35 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study
NCT02511067 · University of Nebraska · PHASE2 · withdrawn · last registry update 2023-08-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding lost and study never started” | – | Registry record, University of Nebraska |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-08-09Also stopped (terminated): Hoffmann-La Roche, Obinutuzumab + Atezolizumab (NCT03866239)
- 2024-07-09Also stopped (terminated): Hoffmann-La Roche, RO7515629 + tocilizumab (NCT05769959)
- 2024-06-26Phase 3 first posted: AO GENERIUM, Complarate® + Actemra® (NCT06475508)
- 2024-06-11Phase 3 first posted: Tianjin Medical University General Hospital, Tocilizumab + Prednisone (NCT06452537)
- 2024-06-07Phase 3 first posted: Zhujiang Hospital, Tocilizumab + NaCl 0.9% 100ml (NCT06447701)
- 2024-06-04Also stopped (terminated): Columbia University, Itacitinib + Tocilizumab (NCT04070781)
- 2024-03-25Results posted on the registry: Hoffmann-La Roche, Glofitamab + Gemcitabine (NCT04313608)
- 2024-03-06Phase 3 first posted: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland, Tocilizumab + Nintedanib (NCT06297096)
- 2024-02-07Results posted on the registry: GlaxoSmithKline, Otilimab (GSK3196165) + csDMARD(s) (NCT04333147)
- 2024-02-07Also stopped (terminated): GlaxoSmithKline, Otilimab (GSK3196165) + csDMARD(s) (NCT04333147)
- 2024-02-02Phase 3 first posted: Suzhou Municipal Hospital of Anhui Province, Tocilizumab + NaCl 0.9% 100ml (NCT06238024)
- 2024-01-17Results posted on the registry: M.D. Anderson Cancer Center, Alemtuzumab + Etoposide (NCT02385110)
- 2023-12-11Results posted on the registry: Hoffmann-La Roche, Tocilizumab (NCT01664598)
- 2023-11-28Also stopped (withdrawn): Sun Yat-sen University, Tocilizumab (NCT06087731)
- 2023-10-30Phase 3 first posted: Hoffmann-La Roche, Satralizumab + Placebo (NCT06106828)
- 2023-10-23Results posted on the registry: Weill Medical College of Cornell University, Tocilizumab + Fludarabine (NCT04395222)
- 2023-10-16Phase 3 first posted: Hoffmann-La Roche, Obinutuzumab + Glofitamab (NCT06084936)
- 2023-10-05Results posted on the registry: Stanford University, Sarilumab + Placebo (NCT04008069)
- 2023-09-21Phase 3 first posted: Zhejiang Hisun Pharmaceutical Co. Ltd., HS628+MTX + Actemra +MTX (NCT06048224)
- 2023-09-15Also stopped (withdrawn): Alonso Vera Torres, Analogs, Prostaglandin E1 + Standard therapeutic protocol (NCT04536363)
- 2023-09-14Phase 3 first posted: Centre Hospitalier Universitaire Dijon, Tocilizumab treatment + Blood samples (NCT06037460)
- 2023-08-14Phase 3 first posted: Hoffmann-La Roche, Satralizumab + Placebo (NCT05987423)
- 2023-08-04Also stopped (terminated): Hoffmann-La Roche, RO7444973 + Tocilizumab (NCT05129280)
- 2023-07-27Phase 3 first posted: Assiut University, Rituximab + IL6 inhibitor (NCT05963048)
- 2023-07-17Results posted on the registry: GlaxoSmithKline, GSK3196165 (Otilimab) + Sarilumab (NCT04134728)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision